This finding corresponds to the conclusion that despite the increased prevalence of GH deficiency in children with DS, the quantitative component of the growth hormone is only one of the possible damaged elements in the GHRH-GH-IGF1 axis in DS patients, and apart from that, an impairment was also detected in GH neurosecretory function and in the bio-activity of GH, both of which are likely to be missed if relying solely on growth hormone stimulation tests (4). This evidence concerns the gene GH1 and Dravet syndrome.